Home / Journals / Journal of Cancer Research and Cellular Interventions / Archives

Review Article

Seeds of Survival: Unraveling the Power and Persistence of Cancer Stem Cells

Authors: Klaunig Y11 Rojanasakul H11 Sanchez E11 Brionne P11 Duncan W11

*Corresponding Author: Sanchez E, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Netherlands

Copyright: © 2025 Sanchez E, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Sanchez E (2025) Seeds of Survival: Unraveling the Power and Persistence of Cancer Stem Cells V1(2)

Received: Aug 08, 2025

Accepted: Aug 12, 2025

Published: Aug 18, 2025

Keywords: immunocompromised models, tumorigenic capacity, Cancer-associated fibroblasts, Potential toxicity

Abstract

Cancer stem cells (CSCs) represent a small yet highly influential subpopulation within tumors, endowed with the ability to self-renew, differentiate, and drive tumor progression. These cells are increasingly recognized as central players in cancer initiation, metastasis, therapeutic resistance, and relapse. This review explores the biological characteristics of CSCs, their origin, molecular signaling pathways, role in tumor heterogeneity, and emerging therapeutic strategies targeting them. Understanding CSCs offers promising avenues for more effective and durable cancer treatments.

Introduction

Cancer remains one of the leading causes of mortality worldwide. Traditional models of tumor biology considered all cancer cells to have equal tumorigenic potential. However, the cancer stem cell hypothesis challenges this notion by proposing that only a subset of cells within a tumor possesses the ability to initiate and sustain cancer growth. These CSCs exhibit properties similar to normal stem cells, including self-renewal and differentiation, but with dysregulated control mechanisms.

Characteristics of Cancer Stem Cells

 Self-Renewal

CSCs can undergo asymmetric division, producing one daughter cell that retains stem-like properties and another that differentiates. This ability sustains the CSC pool and contributes to tumor maintenance.

Differentiation Potential

CSCs can generate heterogeneous populations of cancer cells, explaining the cellular diversity observed within tumors.

Tumorigenicity

Even a small number of CSCs can initiate tumor formation when transplanted into immunocompromised models, highlighting their potent tumorigenic capacity.

Resistance to Therapy

CSCs exhibit resistance to conventional therapies such as chemotherapy and radiation due to:

  • Enhanced DNA repair mechanisms

  • Drug efflux pumps (e.g., ABC transporters)

  • Quiescent (slow-cycling) state

Origin of Cancer Stem Cells

The origin of CSCs remains a subject of debate. Proposed sources include:

  • Normal Stem Cells: Accumulation of mutations in tissue stem cells

  • Progenitor Cells: Partial acquisition of self-renewal ability

  • Differentiated Cells: Dedifferentiation under genetic or environmental influences

Key Signaling Pathways in CSCs

Several conserved pathways regulate CSC maintenance:

  • Wnt/β-catenin Pathway: Controls self-renewal and proliferation

  • Notch Signaling: Influences cell fate decisions

  • Hedgehog Pathway: Regulates embryonic development and CSC survival

  • PI3K/Akt/mTOR Pathway: Promotes growth and survival

Dysregulation of these pathways contributes to CSC persistence and tumor progression.

CSCs and Tumor Microenvironment

The tumor microenvironment (TME) plays a crucial role in maintaining CSC properties. Components include:

  • Cancer-associated fibroblasts (CAFs)

  • Immune cells

  • Hypoxic niches

Hypoxia, in particular, enhances CSC stemness through hypoxia-inducible factors (HIFs), promoting angiogenesis and resistance to therapy.

Role in Metastasis and Recurrence

CSCs are closely linked to metastasis due to their ability to undergo epithelial–mesenchymal transition (EMT), enabling migration and invasion. After treatment, surviving CSCs can regenerate tumors, leading to recurrence.

Identification and Markers of CSCs

CSCs are identified using specific surface markers, which vary by cancer type:

  • CD133 – brain, colon cancers

  • CD44⁺/CD24⁻ – breast cancer

  • ALDH1 – multiple cancers

Functional assays such as sphere formation and tumor initiation in animal models are also used.

Therapeutic Targeting of CSCs

Targeting Signaling Pathways

Inhibitors of Wnt, Notch, and Hedgehog pathways are under investigation.

 Immunotherapy

Strategies include targeting CSC-specific antigens and enhancing immune recognition.

Differentiation Therapy

Inducing CSC differentiation into non-tumorigenic cells.

Nanotechnology-Based Approaches

Nanocarriers can deliver drugs specifically to CSCs, improving efficacy and reducing toxicity.

Challenges and Future Perspectives

Despite advances, several challenges remain:

  • CSC heterogeneity across different cancers

  • Plasticity between CSC and non-CSC states

  • Lack of universal markers

  • Potential toxicity to normal stem cells

Future research should focus on identifying precise biomarkers, understanding CSC plasticity, and developing combination therapies that target both CSCs and bulk tumor cells.

Conclusion
Cancer stem cells play a pivotal role in tumor initiation, progression, metastasis, and therapeutic resistance. Targeting CSCs holds promise for achieving long-term remission and potentially curing cancer. A deeper understanding of their biology will be essential for translating research findings into clinical success.

References

  1. Reya, T.; Duncan, A.W.; Ailles, L.; Domen, J.; Scherer, D.C.; Willert, K.; Hintz, L.; Nusse, R.; Weissman, I.L. A role for Wnt signaling in self-renewal of hematopoietic stem cells. Nature 2003, 423, 409–414.
  2. Ruizi Altaba, A.; Sanchez, P.; Dahmane, N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer 2002, 2, 361–372.
  3. Kunduzova, O.R.; Bianchi, P.; Pizzinat, N.; Escourrou, G.; Seguelas, M.H.; Parini, A.; Cambon, C. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J. 2002, 16, 1129–1131.
  4. Patrawala, L.; Tang, D.G. CD44 as a functional cancer stem cell marker and therapeutic target. In Progress in Gene Therapy: Autologous and Cancer Stem Cell Gene Therapy; Bertolotti, R., Ozawka, K., Eds.; World Scientific: Hacxkensack, NJ, USA, 2008; Volume 3, pp. 317–334.
  5. Parke, D.V. Chemical toxicity and reactive oxygen species. Int. J. Occup. Med. Environ. Health 1996, 9, 331–340.
  6. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1–40.
  7. Levine, B. Eating Oneself and Uninvited Guests: Minireview Autophagy-Related Pathways in Cellular Defense. Cell 2005, 120, 159–162.